Adaptogen cortisol: Bălăceanu-Gurău et al., 2026
This 2025 review synthesizes evidence on how probiotics, postbiotics, adaptogens, and precision nanocarrier delivery systems may influence skin aging through the gut-skin microbiome axis. It is a mechanistic overview, not an intervention trial — it maps pathways but does not test outcomes in humans.
Key takeaways
- The paper reviews mechanisms by which microbiome-active compounds and adaptogens might influence skin aging, but presents no original human data.
- Adaptogens are discussed as modulators of HPA axis stress signaling, cortisol metabolism, and mitochondrial function — all linked to inflammaging and barrier degradation in skin.
- Advanced delivery systems (liposomes, solid lipid nanoparticles, stimuli-responsive carriers) are proposed to improve skin penetration and target-site precision, but human efficacy data are limited.
- This is a narrative review — it compiles existing studies rather than generating new evidence. Useful for mapping the field, but the absence of original trials means we cannot measure effect sizes or reproducibility.
- The authors acknowledge major translational gaps: strain/formulation specificity, incomplete nanocarrier toxicology, regulatory ambiguity, and lack of long-term safety data.
The study
Bălăceanu-Gurău and colleagues published this narrative review in Molecules in 2025 (PubMed). It synthesizes evidence on the endocrine-microbiome-skin axis and evaluates microbiome-directed bioactive strategies — probiotics, prebiotics, postbiotics, synbiotics, phytoestrogens, polyphenols, bioactive peptides, antioxidants, mitochondrial protectors, and adaptogens — for preserving cutaneous homeostasis during aging. The review examines proposed mechanisms in relation to collagen homeostasis, mitochondrial function, lipid barrier integrity, immune regulation, microbial metabolite signaling, and systemic endocrine-metabolic status. It also covers advanced delivery platforms (liposomes, solid lipid nanoparticles, nanostructured lipid carriers, polymeric nanocarriers, nanoemulsions, encapsulated microbiome-active systems, stimuli-responsive carriers) and their potential to improve compound stability, skin retention, controlled release, and target-site precision. No original experiments were conducted; the paper aggregates findings from published studies.
How to read this study
What this paper does well: It maps a complex system — the gut-skin axis, endocrine signaling, microbiome dysbiosis, and delivery pharmacokinetics — in a single conceptual framework. The authors cite primary literature on each compound class and acknowledge translational limitations openly. For researchers trying to understand where the field stands on microbiome-directed aging interventions, this is a useful starting reference.
What this paper is missing: It is a narrative review, not a systematic review or meta-analysis. That means the authors selected studies based on relevance and familiarity, not according to a pre-registered, reproducible search protocol. We do not know if they missed important negative trials or over-weighted positive ones. No effect sizes, confidence intervals, or heterogeneity statistics are reported. The paper describes mechanisms without outcomes — pathways are outlined (e.g., adaptogens modulate HPA axis cortisol, mitochondrial biogenesis, NF-κB signaling), but human trials measuring skin elasticity, wrinkle depth, or barrier function are sparse or absent. Mechanism is hypothesis, not proof.
How I weight this paper: I treat this as a field map, not as evidence for specific interventions. It tells me where to look for trials worth reading, but does not itself establish efficacy. If you are considering an adaptogen or probiotic for skin aging, this review will not answer whether it works in humans — it will tell you what the proposed pathway is and flag that long-term safety data are incomplete. For decision-making, look for the primary RCTs cited within the review and evaluate those individually.
What they found
The authors describe adaptogens (including ashwagandha, rhodiola, schisandra, and bacopa) as compounds that modulate hypothalamic-pituitary-adrenal (HPA) axis activity, cortisol secretion rhythms, and mitochondrial stress responses. Chronic HPA activation — elevated cortisol, disrupted circadian rhythms — is linked to inflammaging, collagen degradation via matrix metalloproteinase upregulation, impaired lipid barrier synthesis, and microbiome dysbiosis. Adaptogens are proposed to normalize cortisol signaling, reduce oxidative stress through Nrf2 pathway activation, support mitochondrial biogenesis via PGC-1α, and dampen pro-inflammatory NF-κB cascades.
The review notes that probiotics and postbiotics (short-chain fatty acids, bacteriocins, exopolysaccharides) may improve skin barrier function by modulating tight junction proteins, reducing transepidermal water loss, and shifting systemic immune tone toward regulatory phenotypes. Phytoestrogens and polyphenols are discussed as modulators of estrogen receptor signaling and antioxidant enzyme induction. Advanced delivery systems are proposed to overcome poor skin penetration and low bioavailability — liposomes and solid lipid nanoparticles encapsulate hydrophilic or lipophilic actives, stimuli-responsive carriers release payload in response to pH, temperature, or enzyme gradients.
No original human outcome data are presented. The review compiles findings from animal models, in vitro keratinocyte and fibroblast cultures, and a limited number of small human trials cited in the bibliography. Effect sizes, statistical significance, and reproducibility across studies are not systematically evaluated.
What it means for the average man
If you are considering an adaptogen or probiotic for skin health, this review maps the proposed pathways — HPA axis modulation, mitochondrial support, microbiome signaling — but does not provide effect sizes or safety timelines from rigorous human trials. The mechanisms are plausible, but plausibility is not efficacy. Before committing to a regimen, look for the individual RCTs cited in the review's bibliography and evaluate them for power, duration, dropout rate, and clinical endpoints (e.g., wrinkle depth, elasticity, transepidermal water loss) rather than surrogate markers (e.g., gene expression, cytokine levels).
The delivery system discussion is primarily theoretical. Nanocarrier formulations may improve penetration, but incomplete toxicology and regulatory ambiguity mean long-term safety is unknown. Until human trials with these systems report multi-year follow-up, approach encapsulated or stimuli-responsive formulations with caution.
The caveats
This is a narrative review, not a systematic review or meta-analysis. The authors selected studies based on relevance, not according to a reproducible search protocol, which introduces potential selection bias. No effect sizes, confidence intervals, or statistical heterogeneity are reported. The paper emphasizes mechanisms — gene expression changes, pathway modulation — rather than clinical outcomes like skin elasticity or wrinkle depth. Mechanism without outcome is hypothesis, not proof. The authors acknowledge major translational gaps: strain and formulation specificity for probiotics, insufficient long-term safety data for adaptogens and nanocarriers, incomplete nanocarrier toxicology, and regulatory ambiguity. No funding source or conflicts of interest are disclosed in the abstract.
Frequently asked questions
Should I trust a review paper over an individual trial?
It depends on the type of review. A systematic review with meta-analysis uses a pre-registered search protocol, evaluates study quality, and pools effect sizes across trials — that is stronger evidence than a single RCT. A narrative review like this one compiles studies the authors found relevant, but does not follow a reproducible protocol or quantify heterogeneity. It is useful for understanding the field and identifying primary sources, but it does not generate new evidence or replace individual trial evaluation.
Do adaptogens lower cortisol in humans?
Some RCTs show ashwagandha (300-600 mg/day standardized extract) reduces serum cortisol by 10-30% at 8-12 weeks in stressed adults. Other adaptogens (rhodiola, schisandra) have smaller or less consistent effects. This review describes the HPA axis pathway but does not report effect sizes or confidence intervals from those trials. For decision-making, read the primary RCTs individually and check for sample size, blinding, and dropout rate.
Are nanocarrier delivery systems safe for long-term use?
The authors explicitly state that nanocarrier toxicology is incomplete and long-term safety data are limited. Liposomes and solid lipid nanoparticles have decades of use in pharmaceuticals, but stimuli-responsive and polymeric carriers are newer. Until multi-year human trials report safety outcomes, approach encapsulated formulations with caution, especially for chronic use.
Does this review prove probiotics improve skin aging?
No. The review describes proposed mechanisms — microbiome metabolite signaling, tight junction protein modulation, immune tone shifts — but does not present original human data or effect sizes. It cites small trials on skin hydration and transepidermal water loss, but acknowledges strain and formulation specificity as major gaps. This is a field map, not proof of efficacy.
Sources
- Bălăceanu-Gurău B., Sotiri I., Girštautė P., Șmocot-Stănescu A., Voinea I., Bărbulescu A., et al. Microbiome-Directed Bioactive Strategies in Skin Aging: Mechanistic Insights and Precision Nanocarrier Delivery Approaches. Molecules 2026. PubMed
- Chandrasekhar K., Kapoor J., Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med 2012;34(3):255-262.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
